Tysabri Withdrawn Pending Analysis Of Safety Signal In Long-Term Trial
Executive Summary
Biogen Idec and Elan are convening a panel of experts on progressive multifocal leukoencephalopathy as the first step towards reintroducing the multiple sclerosis therapy Tysabri (natalizumab)
You may also be interested in...
Biogen Seeks Tysabri Magic TOUCH Again: REMS Allows Rapid PML Response
Biogen Idec developed TOUCH, the restricted distribution risk management plan for its monoclonal antibody Tysabri (natalizumab), to save that product from market withdrawal in 2005-2006
Biogen Seeks Tysabri Magic TOUCH Again: REMS Allows Rapid PML Response
Biogen Idec developed TOUCH, the restricted distribution risk management plan for its monoclonal antibody Tysabri (natalizumab), to save that product from market withdrawal in 2005-2006
Firms Tighten Tysabri Indication To Gain Panel Endorsement For Crohn’s
Given safety issues linked to Biogen Idec/Elan's Tysabri (natalizumab), the companies are narrowing the scope of the requested Crohn's disease indication from that initially proposed and studied in the clinical trials